msb0011359c
mAbexperimentalMulti-specific
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2015 (NCT02517398)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- msb0011359c
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04491955 | Phase 2 | Sep 22, 2020 | National Cancer Institute (NCI) |
| NCT03315871 | Phase 2 | Mar 20, 2018 | National Cancer Institute (NCI) |
| NCT02699515 | Phase 1 | Mar 11, 2016 | Merck KGaA |
| NCT02517398 | Phase 1 | Aug 31, 2015 | Merck KGaA, Merck Serono |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 2 | 1 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 2018 |
| Merck Serono | For profit | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1